Johnson & Johnson Defined Benefit Plan, Effect of One Percentage Point Decrease on Accumulated Postretirement Benefit Obligation
Johnson & Johnson (JNJ) reported Defined Benefit Plan, Effect of One Percentage Point Decrease on Accumulated Postretirement Benefit Obligation of $246.00 million for the 12-month period ending 2019-12-29, per its 10-K filed 2020-02-18.
Discontinued › Notes › Compensation Related Costs › Defined Benefit Plan › Defined Benefit Plan, Effect of One-Percentage-Point Change in Assumed Health Care Cost Trend Rate
us-gaap:DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnAccumulatedPostretirementBenefitObligation1 · last filed 2020-02-18
- Johnson & Johnson defined benefit plan, effect of one percentage point decrease on accumulated postretirement benefit obligation for fiscal 2019 was $246.00M, a 12.14% decline from fiscal 2018.
- Johnson & Johnson defined benefit plan, effect of one percentage point decrease on accumulated postretirement benefit obligation for fiscal 2018 was $280.00M, a 3.78% decline from fiscal 2017.
- Johnson & Johnson defined benefit plan, effect of one percentage point decrease on accumulated postretirement benefit obligation for fiscal 2017 was $291.00M, a 10.46% decline from fiscal 2017.
- Johnson & Johnson defined benefit plan, effect of one percentage point decrease on accumulated postretirement benefit obligation for fiscal 2017 was $325.00M, a 0.31% decline from fiscal 2016.
| Period end | Defined Benefit Plan, Effect of One Percentage Point Decrease on Accumulated Postretirement Benefit Obligation 12 month |
|---|---|
| 2019-12-29 | $246.00M 10-K · filed 2020-02-18 |
| 2018-12-30 | $280.00M 10-K · filed 2019-02-20 |
| 2017-12-31 | $291.00M 10-K · filed 2018-02-21 |
| 2017-01-01 | $325.00M 10-K · filed 2017-02-27 |
| 2016-01-03 | $326.00M 10-K · filed 2016-02-24 |
| 2014-12-28 | $444.00M 10-K · filed 2015-02-24 |
| 2013-12-29 | $347.00M 10-K · filed 2014-02-21 |
| 2012-12-30 | $394.00M 10-K · filed 2013-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |